Disposition kinetics of quinidine. 1976

C T Ueda, and D S Hirschfeld, and M M Scheinman, and M Rowland, and B J Williamson, and B S Dzindzio

The disposition kinetics of quinidine in 12 hospitalized patients in whom oral quinidine therapy was to be initiated is described. Quinidine in doses of 2.6 to 5.2 mg/kg base were infused intravenously over 22 min. Plasma samples were collected during the postinfusion for 24 hr and analyzed by a specific and sensitive assay procedure. In the 12 hr after administration, postinfusion plasma quinidine concentration decay was described by a biexponential equation. Attempts to include the 24-hr data point in the fitting procedures resulted in poorer agreements between the theoretical and experimental curves. A 2-compartment open model is proposed to describe the disposition of quinidine. The volume of the central pool (Vc) and steady-state volume of distribution (Vdss) were 0.91 +/- 0.11 L/kg and 3.03 +/- 0.25 L/kg, respectively, and indicate that quinidine distribution is predominantly extravascular. Quinidine distribution was quite rapid (t1/2alpha = 7.19 +/- 0.70 min), while the apparent elimination half-life (t1/2beta) was considerably longer, 6.333 +/- 0.47 hr. Total body plasma clearance ranged from 1.49 to 7.15 ml/min/kg (mean 4.70) and is primarily associated with nonrenal mechanisms of drug elimination. Urine specimens collected for 48 hr indicated that 17% of the dose is excreted intact and that urinary excretion was essentially complete within 24 hr. Renal clearance (Clr) was 0.80 +/- 0.18 ml/min/kg. The study demonstrated that there is substantial interpatient variability with respect to quinidine disposition.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D008954 Models, Biological Theoretical representations that simulate the behavior or activity of biological processes or diseases. For disease models in living animals, DISEASE MODELS, ANIMAL is available. Biological models include the use of mathematical equations, computers, and other electronic equipment. Biological Model,Biological Models,Model, Biological,Models, Biologic,Biologic Model,Biologic Models,Model, Biologic
D011802 Quinidine An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission. Adaquin,Apo-Quinidine,Chinidin,Quincardine,Quinidex,Quinidine Sulfate,Quinora,Apo Quinidine,Sulfate, Quinidine
D003201 Computers Programmable electronic devices designed to accept data, perform prescribed mathematical and logical operations at high speed, and display the results of these operations. Calculators, Programmable,Computer Hardware,Computers, Digital,Hardware, Computer,Calculator, Programmable,Computer,Computer, Digital,Digital Computer,Digital Computers,Programmable Calculator,Programmable Calculators
D005260 Female Females
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

C T Ueda, and D S Hirschfeld, and M M Scheinman, and M Rowland, and B J Williamson, and B S Dzindzio
June 1976, Research communications in chemical pathology and pharmacology,
C T Ueda, and D S Hirschfeld, and M M Scheinman, and M Rowland, and B J Williamson, and B S Dzindzio
May 1976, Clinical pharmacology and therapeutics,
C T Ueda, and D S Hirschfeld, and M M Scheinman, and M Rowland, and B J Williamson, and B S Dzindzio
March 1977, The Journal of pharmacology and experimental therapeutics,
C T Ueda, and D S Hirschfeld, and M M Scheinman, and M Rowland, and B J Williamson, and B S Dzindzio
July 1979, Journal of clinical pharmacology,
C T Ueda, and D S Hirschfeld, and M M Scheinman, and M Rowland, and B J Williamson, and B S Dzindzio
July 1982, Journal of pharmaceutical sciences,
C T Ueda, and D S Hirschfeld, and M M Scheinman, and M Rowland, and B J Williamson, and B S Dzindzio
October 1983, British journal of clinical pharmacology,
C T Ueda, and D S Hirschfeld, and M M Scheinman, and M Rowland, and B J Williamson, and B S Dzindzio
February 1978, Clinical pharmacology and therapeutics,
C T Ueda, and D S Hirschfeld, and M M Scheinman, and M Rowland, and B J Williamson, and B S Dzindzio
January 1992, Advances in experimental medicine and biology,
C T Ueda, and D S Hirschfeld, and M M Scheinman, and M Rowland, and B J Williamson, and B S Dzindzio
April 2004, Journal of veterinary pharmacology and therapeutics,
C T Ueda, and D S Hirschfeld, and M M Scheinman, and M Rowland, and B J Williamson, and B S Dzindzio
October 1989, Journal of pharmacobio-dynamics,
Copied contents to your clipboard!